Amarin Corporation has completed enrolment for its Phase III clinical trial of triglyceride-lowering drug AMR101.
The 12-week study is designed to evaluate the efficacy and safety of 2gm and 4gm of AMR101 in 229 patients with fasting triglyceride levels greater than or equal to 500mg/dl, according to the company.
These patients are considered to have very high triglyceride levels, according to the National Cholesterol Education Programme Adult Treatment Panel III treatment guidelines.
The trial will be double-blind, multi-centre, placebo-controlled and randomised. Results are expected in early 2011.